All In Biotech

Drug Trial Radar · NCT06532006

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Trastuzumab and Chemotherapy (XELOX) With or Without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer

Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

550

Planned (sponsor's estimate)

Start

Nov 22, 2024

Primary completion

Jun 1, 2027

Study completion Sep 1, 2028

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
Collaborators
Henlius USA
First posted
Aug 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with HER2-positive locally advanced/metastatic adenocarcinoma of the gastric and/or gastroesophageal junction (G/GEJ).Eligible subjects will be randomized to the two groups based on a 1:1 ratio. Enrolled subjects shall be treated with the study drug until the loss of clinical benefit, death, intolerable toxicity, withdrawal of informed consent, or other reasons specified by the protocol (whichever occurs first).

Conditions

  • Gastroesophageal-junction Cancer
  • Monoclonal Antibody
  • Gastric Cancer
  • HER2-positive Gastric Cancer

Interventions

  • HLX22Drug

    HLX22 15mg/kg Q3w

  • PembrolizumabDrug

    Pembrolizumab 200mg q3w

  • TrastuzumabDrug

    Trastuzumab 8 mg/kg loading dose and then 6 mg/kg maintenance thereafter ,Q3W

  • OxaliplatinDrug

    Oxaliplatin 130 mg/m2 ,Q3W

  • CapecitabineDrug

    Capecitabine 1000 mg/m2 bid on Days 1-14 ,Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)per RECIST 1.1 assessed by IRRC(Independent Radiology Review Committee)Time frame: Up to 5 years
  2. Overall Survival (OS)Time frame: Up to 5 years

Locations

208 sites in 17 countries. Site status is shown where the registry gives one.

  • Los Angeles Cancer Network

    Anaheim, California · Recruiting

  • OPN - Oncology Physician Network (Los Alamitos)

    Los Alamitos, California · Recruiting

  • Banner MD Anderson Cancer Center

    Greeley, Colorado · Recruiting

  • Advanced Research LLC

    Deerfield Beach, Florida · Recruiting

  • Florida Cancer Specialist - South

    Fort Myers, Florida · Recruiting

  • BRCR Medical Center

    Plantation, Florida · Recruiting

  • Napa Research

    Pompano Beach, Florida · Recruiting

  • Florida Cancer Specialist - North

    St. Petersburg, Florida · Recruiting

  • Florida Cancer Specialist - East

    West Palm Beach, Florida · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • Mission Cancer + Blood (Exigent Network)

    Des Moines, Iowa · Recruiting

  • Holden Comprehensive Cancer Center - University of Iowa

    Iowa City, Iowa · Recruiting

  • Washington University School of Medicine St. Louis

    St Louis, Missouri · Recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • Comprehensive Cancer Centers Nevada

    Las Vegas, Nevada · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Guthrie Medical Group, PC and Robert Packer Hospital (Guthrie Cancer Center - Sayre)

    Sayre, Pennsylvania · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • HCA Midwest Health

    Nashville, Tennessee · Recruiting

  • Texas Oncology - West (SCRI)

    Abilene, Texas · Recruiting

  • Texas Oncology Central South (SCRI)

    Austin, Texas · Recruiting

  • Texas Oncology Northeast (SCRI)

    Denton, Texas · Recruiting

  • The University of Texas MD Anderson cancer Center

    Houston, Texas · Recruiting

  • Texas Oncology - Gulf Coast (SCRI)

    Webster, Texas · Recruiting

  • American Oncology Network Vista Oncology Division

    Olympia, Washington · Recruiting

  • Northwest Medical Specialties

    Tacoma, Washington · Recruiting

  • West Virginia University Cancer Institute

    Morgantown, West Virginia · Recruiting

  • Fundacion CENIT

    Buenos Aires, Argentina · Recruiting

  • IONC Instituto Oncologico de Cordoba

    Córdoba, Argentina · Recruiting

  • Instituto San Marcos

    San Juan, Argentina · Recruiting

  • CER - Centro de Rehabilitacion Medica San Juan

    San Juan, Argentina · Recruiting

  • Exelsus

    San Miguel de Tucumán, Argentina · Recruiting

  • Centro de Investigacion Pergamino SA

    Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Centro de Investigaciones Clinicas. Clinica Viedma S.A.

    Viedma, Río Negro Province, Argentina · Recruiting

  • União Brasileira de Educação e Assistência

    Puerto Alegre, RS, Argentina · Recruiting

  • Instituto de Oncologia de Rosario

    Cordoba, Santa Fe Province, Argentina · Recruiting

  • Centro Médico Privado CEMAIC

    Cordoba, Santa Fe Province, Argentina · Not yet recruiting

  • Sanatorio Plaza - Fundacion Pita

    Rosario, Santa Fe Province, Argentina · Recruiting

Showing 40 of 208 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.